drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
An autologous tumor-infiltrating lymphocyte (TIL) therapy manufactured from a patient's tumor, containing polyclonal CD8+ and CD4+ T cells that recognize patient-specific tumor antigens via the TCR–MHC pathway and mediate cytotoxic killing.
nci_thesaurus_concept_id
C120552
nci_thesaurus_preferred_term
Lifileucel
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patients tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.
drug_mesh_term
Lifileucel
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, ex vivo–expanded polyclonal CD8+ and CD4+ tumor-infiltrating T cells that recognize patient-specific tumor antigens via TCR–MHC interactions and kill tumor cells through perforin/granzyme-mediated cytotoxicity. Lymphodepleting chemotherapy enhances engraftment, and high-dose IL-2 supports in vivo expansion and persistence.
drug_name
Lifileucel
nct_id_drug_ref
NCT06481592